Vestibular Schwannoma

1. 0:00Vestibular schwannoma is the imaging-anchored disease. The audiogram and the patient's history identify who to image. The MRI is the diagnostic test. DVA and the rest of the vestibular battery serve as supporting evidence and as monitoring tools — they don't make the diagnosis.
2. 0:25The tumour is a benign Schwann-cell neoplasm arising from the vestibular branch of the eighth cranial nerve, most often the inferior vestibular division. It grows slowly — typically about one millimetre per year — within the internal auditory canal and the cerebellopontine angle. Sporadic tumours are unilateral; bilateral tumours raise suspicion of neurofibromatosis type 2.
3. 0:55The classic presentation is asymmetric sensorineural hearing loss, typically high-frequency and slowly progressive, plus unilateral tinnitus and a vague sense of imbalance. Rotational vertigo is uncommon because the slow tumour growth allows continuous central compensation.
4. 1:25The MRI gold standard is gadolinium-enhanced T1 imaging of the internal auditory canal. The audiogram is the screening test that identifies who should have an MRI. Any unilateral or asymmetric sensorineural hearing loss warrants imaging, full stop. Audiometric screening protocols cannot reliably exclude schwannoma — the Bayraktar 2022 meta-analysis and the Reilly 2024 deep-learning study both concluded that no audiometric pattern is sensitive enough to forgo MRI.
5. 2:00The vestibular test battery has variable sensitivity. The West 2020 cohort reported caloric sensitivity of 93%, vHIT 80%, and cVEMP 73%. No single vestibular test is sensitive enough to exclude the diagnosis. DVA correlates with vHIT findings — when vHIT is abnormal, DVA is usually abnormal too — but DVA is also often normal because slow tumour growth allows the central nervous system to compensate.
6. 2:35Where DVA earns its keep here is post-surgically. After translabyrinthine resection, the vestibular function on the affected side is abolished. The patient now has an acute unilateral vestibulopathy on top of an already-compensated chronic lesion. DVA quantifies the deficit, and vestibular rehabilitation tracked by DVA is the standard post-operative care.

What is a vestibular schwannoma?

A vestibular schwannoma is a benign tumour of Schwann cells — the glial cells that myelinate peripheral nerves — arising from the vestibular branch of the eighth cranial nerve. Most arise from the inferior vestibular division. The tumour begins within the internal auditory canal (IAC) and grows medially out into the cerebellopontine angle (CPA) as it enlarges.³⁷

Growth is typically slow — about 1 mm per year on average — which allows the central nervous system continuous opportunity to compensate. Acute rotational vertigo is uncommon at presentation; patients more often describe vague unsteadiness, asymmetric hearing loss, and unilateral tinnitus.³⁷

How common is it?

Detected incidence has risen substantially over recent decades — from roughly 1 per 100,000 person-years in the 1970s to 3–5 per 100,000 person-years today. The increase is largely attributable to MRI availability and incidental detection on imaging performed for unrelated reasons, rather than a true epidemiological rise. The tumour typically presents in the fourth to sixth decade and affects men and women equally.^36,37

Bilateral schwannomas are the hallmark of neurofibromatosis type 2 (NF2), an autosomal-dominant genetic disorder. Five per cent of patients with apparently sporadic schwannomas develop contralateral disease and should be assessed for NF2.³⁷

Who needs MRI?

Any patient with unilateral or asymmetric sensorineural hearing loss, unilateral non-pulsatile tinnitus, or unexplained unilateral vestibular dysfunction warrants gadolinium-enhanced MRI of the internal auditory canal. The 2020 European Association of Neuro-Oncology (EANO) guideline considers this the diagnostic gold standard.³⁷

Multiple audiometric screening protocols have been proposed — "rule of 3000," asymmetry of ≥15 dB at adjacent frequencies, asymmetric speech discrimination, and so on. Systematic review and recent deep-learning analysis show that no audiometric pattern is sensitive enough to reliably exclude schwannoma in a patient where it is clinically suspected.³⁷ The screening question is not whether the audiogram is "abnormal enough" — it is whether the asymmetry is unexplained.

The vestibular test battery

West and colleagues (2020) reported test-battery sensitivity in 59 patients with surgically confirmed unilateral vestibular schwannoma:³⁵

• Caloric test: 93% sensitivity
• vHIT: 80% sensitivity
• cVEMP: 73% sensitivity

Several patterns are worth recognising:

• Caloric weakness with normal vHIT is the single most common pattern — analogous to the Ménière's dissociation but for a different reason. The slow tumour growth allows compensation that masks the rotational deficit at high frequencies even when low-frequency function (caloric) is impaired.³⁵
• cVEMP loss reflects the tumour's preferential arising from the inferior vestibular division.³⁷
• Posterior canal vHIT abnormality with preserved horizontal canal vHIT can be the earliest vestibular sign — again reflecting inferior division origin. Worth looking for if only horizontal vHIT is performed and is normal.

Where DVA fits

DVA is neither sensitive nor specific enough to screen for or to exclude vestibular schwannoma. Older estimates report sensitivity around 81% and specificity around 53% — useful as supporting evidence but never as a primary diagnostic test.^1,35

Three contexts in which DVA earns its keep in this disease:

• Pre-operative baseline. If the patient is heading to surgery, a documented baseline DVA frames how much functional loss the surgery will add and how much rehabilitation will be needed.
• Post-operative monitoring. Translabyrinthine resection ablates vestibular function on the affected side. DVA quantifies the acute deficit, then tracks recovery through covert catch-up saccades over weeks to months. This is the same trajectory seen after intratympanic gentamicin in Ménière's and after vestibular neuritis recovery.^3,5
• Surveillance during observation. Many small tumours are managed with serial MRI rather than surgery. A patient developing oscillopsia or DVA decline during observation may have growth even if MRI changes are subtle. DVA is not a replacement for imaging, but it is a useful symptom-anchored adjunct.

Management overview

The EANO 2020 guideline frames three principal management options, chosen against tumour size, growth rate, age, hearing status, and patient preference:³⁷

• Observation with serial MRI.The default for small (< 15 mm intracanalicular) or incidentally detected tumours with limited symptoms. Most show slow or absent growth.
• Stereotactic radiotherapy / radiosurgery. For small to medium tumours. Aims to halt growth rather than to remove. Hearing preservation rates depend on baseline hearing and tumour size.
• Microsurgical resection. For large tumours, those causing brainstem compression, those failing radiotherapy, or where patient preference favours definitive treatment. Three principal approaches: translabyrinthine (sacrifices hearing; widest exposure for large tumours), retrosigmoid (preserves hearing where feasible), and middle cranial fossa (best for small intracanalicular tumours with serviceable hearing).

Post-surgical DVA: a unilateral vestibulopathy in slow motion

Translabyrinthine resection abolishes vestibular function on the tumour side. The clinical picture immediately after surgery resembles acute vestibular neuritis — spontaneous nystagmus, severe unsteadiness, asymmetric DVA. The trajectory is then identical to neuritis recovery: static compensation removes the spontaneous nystagmus over days to weeks, and structured vestibular rehabilitation drives DVA recovery over weeks to months.^3,5,25

Two practical patterns deserve attention:

• Pre-existing compensation accelerates recovery. A patient with long-standing tumour growth has often already compensated centrally for much of the vestibular asymmetry. After surgery the recovery is therefore faster than after an acute neuritis of similar magnitude — the brain has had years of practice.
• Older patients compensate more slowly and may never fully recover DVA. The Anson 2016 data on age and compensatory saccades is relevant here: older brains generate larger but later catch-up saccades. Plan rehabilitation timing accordingly.¹⁵

Differential diagnosis

• Sudden sensorineural hearing loss (SSNHL) — but schwannoma can rarely present this way too. SSNHL workup should include MRI to exclude tumour.
• Meningioma of the CPA — distinguishable on MRI by wider base on the petrous bone and dural tail. Vestibular tests may be similar.
• Epidermoid cyst of the CPA — distinct MRI signal (high T2, DWI restriction).
• Facial schwannoma in the IAC — rare; facial weakness disproportionate to hearing loss.
• Ménière's disease — episodic vertigo plus low-frequency fluctuating SNHL distinguishes from the high-frequency progressive pattern of schwannoma. Caloric–vHIT dissociation occurs in both; MRI is the discriminator.^32,35

Reading the report

A patient with unilateral or asymmetric sensorineural hearing loss, disproportionately reduced speech discrimination, and an enhancing mass in the IAC or CPA on gadolinium-enhanced MRI has a vestibular schwannoma until proven otherwise.³⁷ Vestibular findings — including DVA — are supporting evidence and matter most for surgical planning and post-operative care. A normal DVA does not exclude the diagnosis; an abnormal DVA does not establish it.³⁵